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This Article contains errors in Figs 1 and 8 that were introduced during the production process. The compound on the lower right side
of Fig. 1 is labelled incorrectly and should be labelled ‘SC83288’. The correct version of Fig. 1 appears below as Fig. 1. In Fig. 8c,
‘SC83458 selected’ should read ‘SC81458 selected’ and in Fig. 8d ‘SC81758’ should read ‘SC81458’. The correct version of Fig. 8 appears






MM 296 g mol–1
Amicarbalide
IC50 10 nM
MM 502 g mol–1
SC09064
IC50 8 nM
MM 628 g mol–1
SC81458
IC50 3 nM
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